Ignite Creation Date:
2025-12-25 @ 2:32 AM
Ignite Modification Date:
2026-03-04 @ 10:25 PM
Study NCT ID:
NCT02392234
Status:
COMPLETED
Last Update Posted:
2018-06-12
First Post:
2015-03-12
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation
Sponsor:
Vertex Pharmaceuticals Incorporated
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-03
Start Date Type:
None
Primary Completion Date:
2017-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-02
Completion Date Type:
ACTUAL
First Submit Date:
2015-03-12
First Submit QC Date:
None
Study First Post Date:
2015-03-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-03-14
Results First Submit QC Date:
None
Results First Post Date:
2018-06-12
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2018-02-14
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2018-05-08
Last Update Post Date:
2018-06-12
Last Update Post Date Type:
ACTUAL